8-K

                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15 (d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

         Date of Report (Date of earliest event reported): June 2, 2003

                            POINT THERAPEUTICS, INC.
               (Exact Name of Registrant as Specified in Charter)


                          DELAWARE                    0-19410
              (State or Other Jurisdiction   (Commission File Number)
                       of Incorporation)

                 125 SUMMER STREET, BOSTON, MASSACHUSETTS 02110
                    (Address of Principal Executive Offices)

       Registrant's telephone number, including area code: (617) 933-2130

                                       N/A

          (Former Name or Former Address, if Changed Since Last Report)





Item 7.           Financial Statements and Exhibits.

                  (c) Exhibits.

                  99.1 - Press release issued by Point Therapeutics, Inc., dated
                  June 2, 2003.

Item 9.           Regulation FD Disclosure.

                  Point Therapeutics, Inc. issued a press release on June 2,
                  2003 announcing the presentation of results from a study of
                  its lead product candidate PT-100, demonstrating
                  immunostimulatory effects and tumor growth suppression in
                  mice. The results were presented in abstract form at the 2003
                  annual meeting of the American Society of Clinical Oncology in
                  Chicago, IL.

                  A copy of the press release dated June 2, 2003 is being filed
                  as Exhibit 99.1 to this Current Report on Form 8-K.



                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                  POINT THERAPEUTICS, INC.


  June 2, 2003                    By:       /s/ Donald R. Kiepert, Jr.
                                          -------------------------
                                  Name:   Donald R. Kiepert, Jr.
                                  Title:  President, Chief Executive Officer








                                  EXHIBIT INDEX

The following exhibit is filed herewith:

Exhibit     Description
- -------     -----------
99.1        Point Therapeutics, Inc. issued a press release on June 2,
            2003 announcing the presentation of results from a study of
            its lead product candidate PT-100, demonstrating
            immunostimulatory effects and tumor growth suppression in
            mice. The results were presented in abstract form at the 2003
            annual meeting of the American Society of Clinical Oncology in
            Chicago, IL.

EX-99

                                                                   Exhibit 99.1

                              FOR IMMEDIATE RELEASE


Contact:
Richard N. Small
Senior Vice President, Chief Financial Officer
617-933-2130

Ritu Baral
The Trout Group
212-477-4007 ext. 25
(investor relations)

  INVESTIGATORS REPORT RESULTS OF STUDIES WITH POINT THERAPEUTICS' PT-100, AN
               ANTI-TUMOR SMALL MOLECULE THAT AMPLIFIES IMMUNITY

BOSTON, MA. (BUSINESS WIRE)--June 2, 2003--Point Therapeutics, Inc. (OTC BB:
POTP) today announced the presentation of results from a study of its lead
product candidate PT-100, demonstrating immunostimulatory effects and tumor
growth suppression in mice. The results were presented in abstract form at the
2003 annual meeting of the American Society of Clinical Oncology in Chicago, IL.

The study showed that oral treatment with PT-100 in tumor-bearing mice
significantly suppressed tumor growth and also increased the expression of
certain chemokines and cytokines within the tumor and local lymph nodes. The
chemokines and cytokines involved in the response to PT-100 treatment are known
to promote immune responses that can destroy tumor cells. Mice which rejected
syngeneic tumors (that is, tumors derived from the strain of mice used in the
experiments) after PT-100 treatment became specifically resistant to secondary
tumor rechallenge and had increased anti-tumor CTL (cytotoxic T lymphocytes that
have the ability to specifically kill tumor cells) activity. The Company has
demonstrated the anti-tumor activity of PT-100 in a variety of mouse tumor
models.

In addition to T cell immunity, tumor-specific antibodies can also suppress
tumor growth by directing certain effector cells to kill the tumor by a
mechanism known as antibody-dependent cell-mediated cytotoxicity (ADCC).
Neutrophils, natural killer cells and macrophages have the ability to kill tumor
cells by this mechanism. Because these cell types respond to the cytokines and
chemokines increased by PT-100 treatment, the ability of PT-100 to augment the
anti-tumor activity of specific antibodies was investigated. In mice inoculated
with a human B-cell lymphoma, PT-100 was shown to enhance the anti-tumor
activity of Rituxan, a CD20-specific monoclonal antibody, approved for the
treatment of non-Hodgkin's lymphoma (NHL).

The authors conclude that PT-100 has the ability to suppress tumor growth by
promoting the anti-tumor activity of a number of effector cell types. Lead
author Dr. Barry Jones, Points'

                                       1


Senior Vice President of research stated, "By stimulating the production of
chemokines and cytokines within the tumor and regional lymph nodes, PT-100 has
the potential both to activate important immune effector cells and to
concentrate them in the tumor. Because of this unique mechanism of action, we
believe that PT-100 can promote an attack on the tumor by both the T-cell and
antibody-mediated branches of immunity."

As a result of these findings, the Company will be initiating a multicenter,
U.S. Phase 1 / 2 human clinical study to test PT-100 in combination with the
monoclonal antibody Rituxan(R) in patients with NHL or chronic lymphocytic
leukemia (CLL). This trial is expected to start in later this month. The Phase 1
portion of the study will test PT-100 in combination with Rituxan(R) in three to
six patients in four escalating dose groups to investigate the maximum tolerated
dose (MTD) and anti-tumor activity. Phase 1 is expected to be completed by the
first half of 2004. Upon establishing an MTD, Phase 2 will commence with
Rituxan(R) and PT-100, administered at the determined MTD. The objective of the
Phase 2 portion of the trial is to compare the tumor response rates between
patients receiving the combination of Rituxan(R) and PT-100 and patients
receiving Rituxan(R) alone.


ABOUT POINT THERAPEUTICS, INC.:

Point is a Boston-based biopharmaceutical company developing small molecule
drugs for the treatment of a variety of cancerous tumors and certain
hematopoietic disorders. Point's lead product candidate, PT-100, has the
potential to inhibit the growth of certain cancerous tumors. Point will be
initiating shortly a Phase 1/2 human clinical study to test the safety and
efficacy of PT-100 in combination with Rituxan(R) in patients with hematologic
malignancies, such as NHL and CLL. Point is also developing PT-100 as a
potential therapy for the treatment of hematopoietic disorders caused by
chemotherapy treatments. Point is currently evaluating PT-100 in a human
clinical study in which cancer patients undergoing chemotherapy are treated with
PT-100 for neutropenia.

- --------------------------------------------------------------------------------


Certain statements contained herein are not strictly historical and are "forward
looking" statements as defined in the Private Securities Litigation Reform Act
of 1995. This information includes statements on the prospects for our drug
development activities and results of operations based on our current
expectations, such as statements regarding certain milestones with respect to
our clinical program and our product candidates. Forward-looking statements are
statements that are not historical facts, and can be identified by, among other
things, the use of forward-looking language, such as "believe," "expect," "may,"
"will," "should," "seeks," "plans," "schedule to," "anticipates" or "intends" or
the negative of those terms, or other variations of those terms of comparable
language, or by discussions of strategy or intentions. A number of important
factors could cause actual results to differ materially from those projected or
suggested in the forward looking statement, including, but not limited to, the
ability of the Company to (i) successfully develop products, (ii) obtain the
necessary governmental approvals, (iii) effectively commercialize any products
developed before its competitors and (iv) obtain and enforce intellectual
property rights, as well as the risk factors described in the Company's Annual
Report on Form 10-K for the fiscal year ended December 31, 2002 and from time to
time in the Company's other reports filed with the Securities and Exchange
Commission.

                                       2